Back to top
more

Halozyme Therapeutics, Inc. (HALO)

(Delayed Data from NSDQ)

$19.07 USD

19.07
1,288,090

-0.60 (-3.03%)

Updated Jan 24, 2020 04:00 PM ET

Add to portfolio

2-Buy   2      

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.66%
17.94%
9.57%
5.30%
2.19%
10.75%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

D Value | F Growth | B Momentum | F VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Balance Sheet

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

Research for HALO

   

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

Fiscal Year End for Halozyme Therapeutics, Inc. falls in the month of December.

All items in Millions except Per Share data.

12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Assets          
Cash & Equivalents NA 355 469 205 108
Receivables NA 30 22 16 32
Notes Receivable NA 0 0 0 0
Inventories NA 23 5 15 9
Other Current Assets NA 21 14 21 22
Total Current Assets NA 428 510 257 172
Net Property & Equipment NA 7 4 4 4
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 0 0 0 0
Deposits & Other Assets NA 5 6 1 6
Total Assets NA 440 520 262 182
Liabilities & Shareholders Equity 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Notes Payable NA 0 0 0 0
Accounts Payable NA 4 8 4 5
Current Portion Long-Term Debt NA 92 77 17 22
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 50 40 29 27
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 4 7 5 9
Total Current Liabilities NA 149 131 55 62
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 5 54 40 44
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 35 125 199 28
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 2 1 0 4
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 191 312 294 139
Shareholders Equity 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 780 731 553 526
Retained Earnings NA -531 -522 -585 -483
Other Equity NA -0 -0 0 -0
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 249 208 -32 43
Total Liabilities & Shareholder's Equity NA 440 520 262 182
Total Common Equity 0 249 208 -32 43
Shares Outstanding 146.50 144.50 142.30 129.40 128.00
Book Value Per Share 0.00 1.72 1.46 -0.25 0.34

Fiscal Year End for Halozyme Therapeutics, Inc. falls in the month of December.

All items in Millions except Per Share data.

12/31/2019 9/30/2019 6/30/2019 3/31/2019 12/31/2018
Assets          
Cash & Equivalents NA 238 287 329 355
Receivables NA 41 32 28 30
Notes Receivable NA 0 0 0 0
Inventories NA 36 44 31 23
Other Current Assets NA 27 28 21 21
Total Current Assets NA 342 392 409 428
Net Property & Equipment NA 15 15 15 7
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 0 0 0 0
Deposits & Other Assets NA 13 11 6 5
Total Assets NA 370 418 429 440
Liabilities & Shareholders Equity 12/31/2019 9/30/2019 6/30/2019 3/31/2019 12/31/2018
Notes Payable NA 0 0 0 0
Accounts Payable NA 4 12 4 4
Current Portion Long-Term Debt NA 55 71 87 92
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 46 46 44 50
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 4 7 4 4
Total Current Liabilities NA 108 135 139 149
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 1 2 5 5
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 9 14 19 35
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 7 7 2
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 125 158 169 191
Shareholders Equity 12/31/2019 9/30/2019 6/30/2019 3/31/2019 12/31/2018
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 814 804 789 780
Retained Earnings NA -569 -544 -530 -531
Other Equity NA 0 0 0 -0
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 245 260 260 249
Total Liabilities & Shareholder's Equity NA 370 418 429 440
Total Common Equity 0 245 260 260 249
Shares Outstanding 146.50 146.30 145.50 145.30 144.50
Book Value Per Share 0.00 1.68 1.79 1.79 1.72